Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review
- PMID: 18188838
- PMCID: PMC6878515
- DOI: 10.1002/mpr.229
Methodological approaches in the assessment of interferon-alfa-induced depression in patients with chronic hepatitis C - a critical review
Abstract
In recent years, research on interferon (IFN)-induced depressive symptoms in antivirally treated patients suffering from chronic hepatitis C (CHC) has considerably intensified. Profound scientific knowledge of this complication is of great relevance with regard to adherence, compliance, and premature therapy discontinuation. Presently, there is considerable variability of both, the frequency and extent of IFN-induced depression reported in different cohorts of patients. The aim of the presented study was to systematically review recent literature of research within this field; and particularly (1) to identify to what extent methodological bias contributed to inconsistent results in different studies, (2) to critically appraise methods and results of studies published so far, and (3) to suggest directions for future work, especially with respect to alternative and improved methodological approaches. The results of this critical review suggest that the variability of findings seem to be largely due to different study populations, treatment regimens, methodological approaches, and sometimes arbitrary or at least poorly defined choice of screening instruments for depression, particularly criteria for clinically relevant depression (cut-off criteria). Study designs and methodological approaches to investigate IFN-alfa-induced depression in patients with CHC have been incoherent. Future research in this field needs agreement on the use of standardized assessment of IFN-induced depression in CHC. Furthermore, objective criteria and guidelines for the treatment of IFN-induced depression in these patients are needed in clinical practice.
Similar articles
-
Depressive symptoms in patients with hepatitis C treated with pegylated interferon alpha therapy: a 24-week prospective study.Psychiatr Danub. 2011 Dec;23(4):370-7. Psychiatr Danub. 2011. PMID: 22075738
-
Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms.J Clin Psychiatry. 2005 Aug;66(8):1050-7. doi: 10.4088/jcp.v66n0814. J Clin Psychiatry. 2005. PMID: 16086622
-
Asymmetric dimethylarginine responses during interferon-α-induced depression in patients with chronic hepatitis C infection.Psychosom Med. 2014 Apr;76(3):197-207. doi: 10.1097/PSY.0000000000000042. Psychosom Med. 2014. PMID: 24608038
-
Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C.Curr Med Res Opin. 2009 Apr;25(4):991-1002. doi: 10.1185/03007990902779186. Curr Med Res Opin. 2009. PMID: 19275518 Review.
-
Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects.Curr Drug Abuse Rev. 2008 Jun;1(2):177-87. doi: 10.2174/1874473710801020177. Curr Drug Abuse Rev. 2008. PMID: 19630716 Review.
Cited by
-
Effect of pegylated interferon-α-2a treatment on mental health during recent hepatitis C virus infection.J Gastroenterol Hepatol. 2012 May;27(5):957-65. doi: 10.1111/j.1440-1746.2011.07035.x. J Gastroenterol Hepatol. 2012. PMID: 22142332 Free PMC article. Clinical Trial.
-
Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children.Hepatology. 2011 May;53(5):1468-75. doi: 10.1002/hep.24248. Hepatology. 2011. PMID: 21351116 Free PMC article. Clinical Trial.
-
RNA editing blood biomarkers for predicting mood alterations in HCV patients.J Neurovirol. 2019 Dec;25(6):825-836. doi: 10.1007/s13365-019-00772-9. Epub 2019 Jul 22. J Neurovirol. 2019. PMID: 31332697 Free PMC article. Clinical Trial.
-
Risk factors for the development of depression in patients with hepatitis C taking interferon-α.Neuropsychiatr Dis Treat. 2011;7:275-92. doi: 10.2147/NDT.S13917. Epub 2011 May 15. Neuropsychiatr Dis Treat. 2011. PMID: 21654873 Free PMC article.
-
Recurrence of depressive disorders after interferon-induced depression.Transl Psychiatry. 2017 Feb 7;7(2):e1026. doi: 10.1038/tp.2016.274. Transl Psychiatry. 2017. PMID: 28170005 Free PMC article.
References
-
- Angelino AF, Treisman GJ. Evidence‐informed assessment and treatment of depression in HCV and interferon‐treated patients. Int Rev Psychiatry 2005; 17: 471–6. - PubMed
-
- American Psychiatric Association (APA) . Diagnostic and Statistical Manual of Mental Disorders: DSM‐IV‐TR. Washington, DC: APA, 2000.
-
- Asnis GM, De La Garza R. Interferon‐induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 808–18. - PubMed
-
- Beck AT, Beck RW. Screening depressed patients in family practice. A rapid technic. Postgrad Med 1972; 52: 81–5. - PubMed
-
- Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561–71. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical